Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | APEX1 | P27695 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4433936 | 0.90 | CDC25B (0.50) | KDM4ENOTUMTDP1POLBAPEX1 | |
| SCHEMBL10517562 | 0.87 | ESR1 (0.46) | KDM4ENOTUMTDP1POLBAPEX1 | |
| SCHEMBL26601309 | 0.86 | NR4A1 (0.49) | KDM4ENOTUMTDP1POLBAPEX1 | |
| SCHEMBL26601369 | 0.86 | AKR1C3 (0.49) | KDM4ENOTUMTDP1POLBAPEX1 | |
| SCHEMBL362582 | 0.86 | LMNA (0.57) | KDM4ENOTUMTDP1POLBAPEX1 | |
| SCHEMBL25233228 | 0.86 | RIPK3 (0.45) | KDM4ENOTUMTDP1POLBAPEX1 | |
| SCHEMBL1396731 | 0.85 | MAPK1 (0.58) | KDM4ENOTUMTDP1POLBAPEX1 | |
| SCHEMBL25534175 | 0.84 | POLB (0.41) | KDM4ENOTUMTDP1POLBAPEX1 | |
| SCHEMBL4812121 | 0.83 | ALDH1A1 (0.43) | KDM4ENOTUMTDP1POLBAPEX1 | |
| SCHEMBL25235077 | 0.83 | POLB (0.41) | KDM4ENOTUMTDP1POLBAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103889223-A | Antibacterial compounds and methods for use | PTC THERAPEUTICS INC | 2014-06-25 | — | — | CN | claimed |
| US-20260042765-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORP (US) | 2026-02-12 | — | — | US | disclosed |
| US-12415809-B2 | Pyrrolotriazine compounds as tam inhibitors | INCYTE CORPORATION (US) | 2025-09-16 | — | — | US | disclosed |
| US-12234220-B2 | Immunomodulatory compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| CN-114456175-B | Pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-114456176-B | Pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2024-08-30 | — | — | CN | disclosed |
| EP-3762392-B1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO LTD (KR) | 2024-05-15 | — | — | EP | disclosed |
| US-20240124463-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2024-04-18 | — | — | US | disclosed |
| EP-4321513-A2 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | Incyte Corporation (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-3436461-B1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORP (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-1742948-A2 | BICYCLIC HETEROCYCLES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1737451-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-29 | — | — | US | disclosed |
| WO-2005117867-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005116028-A2 | BICYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-03 | — | — | US | disclosed |
| US-20050239820-A1 | Bicyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-10-27 | — | — | US | disclosed |
| US-4238220-A | PLANT GROWTH REGULATORS; SEEDICIDES | ROHM AND HAAS COMPANY (US) | 1980-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | KDM4E 1251/4885NOTUM 2559/4885TDP1 1391/4885 |
| US-20260042765-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MAP2K2, TTK, MAP2K5 | KDM4E 212/4885NOTUM 1928/4885TDP1 1248/4885 |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | MAP3K5, MAP3K15, MAP4K2 | KDM4E 1105/4885NOTUM 2274/4885TDP1 1195/4885 |
| US-20050239820-A1 | Bicyclic heterocycles as kinase inhibitors | CDK2, ABL1, CDKN1A | KDM4E 613/4885NOTUM 3366/4885TDP1 2274/4885 |
| US-12234220-B2 | Immunomodulatory compounds | CRBN, CD47, CD58 | KDM4E 2386/4885NOTUM 3199/4885TDP1 1998/4885 |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | CDK2, MAP3K19, CDK1 | KDM4E 697/4885NOTUM 3141/4885TDP1 3291/4885 |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | KDM4E 1251/4885NOTUM 2559/4885TDP1 1391/4885 |
| US-12415809-B2 | Pyrrolotriazine compounds as tam inhibitors | MERTK, MAP3K15, MAP3K5 | KDM4E 769/4885NOTUM 4398/4885TDP1 1920/4885 |
| US-20240124463-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MERTK, MAP3K15, MAP3K5 | KDM4E 769/4885NOTUM 4398/4885TDP1 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.